CRL - Charles River Laboratories International Inc.


Gross Profit was Negative


based on last 5 year data.
Income Statement is STRONG
Revenue Growth is 1524.41%
Operating Income Growth is 23.23%
Net Income Growth is 44.55%
Earnings Per Share (EPS) Growth is 42.01%
Net Margin is 12.46%
Balance Sheet is WEAK
Current Asset to Current Liability Ratio is 1.43
Debt Ratio is 0.61
Current Debt to Net Income Ratio is 0.13
Total Debt to Total Assets Ratio is 0.36
Cash Flow is MODERATE
Cash from Operations Growth is 13.65%
Capital Expenditure is High
Net Increase in Cash is Negative
Long Term Score Trend is NEGATIVE
Investment Risk is High
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Charles River Laboratories International Inc. (CRL) -
Industry - Research and Development in Biotechnology
Sector - Professional, Scientific, and Technical Services
CEO - James Foster

Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.